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S U M M A R Y
A 44-year-old female presented with a 3-month history of headache, dizziness, nausea, and vomiting.
Her past medical history was signiﬁcant for long-standing intravenous drug abuse. Shortly after
admission, the patient became hypertensive and febrile, with fever as high as 38.8 8C. The lumbar
puncture proﬁle supported an infectious process; however multiple cultures of blood and cerebrospinal
ﬂuid (CSF) did not initially show growth of organisms. Finally after 9 days of incubation, a CSF culture
showed evidence of a few colonies of Candida albicans. To conﬁrm the diagnosis, preserved CSF from that
sample was tested for (1!3)-b-D-glucan, showing levels >500 pg/ml. This report illustrates a rare
complication of intravenous drug use in an immunocompetent patient and demonstrates the utility of
(1!3)-b-D-glucan testing in possible Candida meningitis.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idCase report
A 44-year-old white female presented with a 3-month history
of headache, dizziness, nausea, and vomiting. Her past medical
history was signiﬁcant for hypertension, intravenous drug abuse
(IVDA), and chronic hepatitis C. The symptoms had started with
daily, intermittent headaches for roughly 3 months before her
admission. The headaches could be exacerbated by light or
screaming, and ibuprofen partially relieved the pain. About a
month following the onset of headaches, she developed gait
instability. She ultimately decided to come to the hospital after
developing severe nausea, vomiting, and dizziness. On further
questioning, she denied any fever, chills, incontinence, sputum
production, hemoptysis, or cough. The patient had a 26-year
history of IVDA. A urine drug screen performed on admission was
positive for buprenorphine, benzodiazepine, and opiates.
On arrival, the patient was afebrile and had a blood pressure
(BP) of 126/92 mmHg and heart rate of 111 bpm. Laboratory test
results, including the complete blood proﬁle and basic metabolic
proﬁle, were grossly normal. A physical examination demonstrat-
ed photophobia, but was otherwise unremarkable. Computed* Corresponding author.
E-mail address: mfarrugia@hsc.wvu.edu (M.K. Farrugia).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tomography (CT) of the brain without contrast showed a
disproportionate prominence of the ventricles relative to the
cortical sulci, raising the question of possible normal pressure
hydrocephalus; magnetic resonance imaging (MRI) of the brain
revealed similar ﬁndings. A chest X-ray showed no focal inﬁltrates,
and HIV antibody testing, as well as PCR testing, was negative. The
patient was admitted with a suspicion of normal pressure
hydrocephalus.
After admission, the patient spiked episodic fevers as high as
38.8 8C. Blood and urine cultures were drawn. The following day,
the patient continued to have episodic fever and also became
hypertensive with a BP of 190/90 mmHg. A subsequent lumbar
puncture demonstrated an opening pressure of 310 mmHg, and
cerebrospinal ﬂuid (CSF) studies showed glucose of 7 mg/dl,
protein of 357 mg/dl, 2  106 red blood cells/l, and 203  106white
blood cells/l, with >50% neutrophils. Gram staining did not reveal
any organisms and CSF cultures were initiated. CSF ﬂow cytometry
showed no evidence of acute leukemia or lymphoma. Additional
CSF assays evaluating possible tuberculosis, syphilis, Epstein–Barr
virus, cytomegalovirus, enterovirus, herpes simplex virus 1 and 2,
and Cryptococcus neoformans were negative. Furthermore, tests for
blastomycosis and histoplasmosis were also negative. The blood
cultures drawn on admission showed no growth in 4 days. She was
then started on empiric vancomycin and piperacillin/tazobactam
for possible bacterial meningitis.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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fever and uncontrolled hypertension. The patient also became
confused and would regularly only be oriented to person and/or
place. An ophthalmological examination revealed papilledema.
Multiple escalations of her blood pressure regimen failed to
achieve control. Ultimately, she was given an anti-hypertensive
regimen consisting of metoprolol 50 mg, clonidine 0.1 mg twice
daily, clonidine 0.1 mg as needed, lisinopril 20 mg daily, and
hydralazine 5 mg every 6 hours as needed; her blood pressure
continued to measure between 154/104 and 224/136 mmHg.
Repeat serology and CSF studies for possible organisms
continued to be negative. Gram staining and India ink staining
did not show any organisms. Repeat CSF cultures, including
bacterial, acid-fast bacilli, and fungal, were started. Serum (1!3)-
b-D-glucan (BDG) was low at 48 pg/ml.
As no organism could be identiﬁed, the patient continued to
receive empiric treatment for bacterial meningitis and supportive
care. Fungal meningitis remained high on the differential given the
chronic presentation and ﬁndings of hydrocephalus. However, due
to the morbidity associated with amphotericin B treatment,
empiric antifungal treatment was not started. The patient
remained hypertensive and experienced episodic fever, requiring
therapeutic large-volume lumbar punctures every 3–4 days. Other
studies, including West Nile virus serum and CSF PCR, as well as
Lyme’s disease serology, were negative. Repeat imaging demon-
strated only small focal enhancement within the midbrain, which
could not be sampled.
On her 16th day in the hospital, the fungal culture from the
second lumbar puncture performed on hospital day 7 grew fewer
than ﬁve colonies of Candida albicans. While it was encouraging to
obtain a potential causative agent, there was concern over possible
contamination given the small yield. To conﬁrm the diagnosis, BDG
testing of saved CSF from the positive culture showed levels
>500 pg/ml. Repeat serum BDG testing was still negative. The
patient began treatment with liposomal amphotericin B; ﬂucyto-
sine was held due to low blood counts. After starting treatment, the
patient’s blood pressure and mentation began to improve. Follow-
up ophthalmological examinations demonstrated resolving papil-
ledema and she was consistently afebrile. After 14 days of
liposomal amphotericin B treatment, the patient was discharged
home on an indeﬁnite course of ﬂuconazole 800 mg.
Discussion
Fungal meningitis is associated with individuals who are
immunocompromised, prolonged antibiotic use, serious burns,
direct inoculation, intravascular catheters, neonates, or those with
intracranial devices such as shunts.1 Cryptococcus meningitis is a
common complication of HIV-induced immunosuppression, while
Candida meningitis is more frequently observed in neonates and
individuals with intracranial instrumentation. In the current case,
the patient lacked any of these known risk factors. Only her history
of IVDA provides any rationale as to how she developed this
infection. In fact, Candida meningitis within an immunocompetent
patient with a history of IVDA has been documented recently.2
The diagnosis of Candida meningitis can be challenging. Fungal
cultures of CSF have a poor sensitivity and can take weeks to grow.
Furthermore, unlike Cryptococcus infections, there is currently no
widely accepted molecular-, antigen-, or nucleic acid-based testing
method to expedite identiﬁcation of the organism, thus delaying
proper treatment. Such limitations necessitate the development of
improved diagnostic assays for involvement of the CNS by Candida.In 2012, several patients developed CNS complications due to
the contamination of methylprednisolone epidural injections with
C. albicans.3 From this outbreak, researchers evaluated the utility of
the BDG assay to improve upon the diagnostic limitations of
traditional culture methods. BDG is a fungal cell wall component
highly enriched in C. albicans, Aspergillus, and other fungal species.
Notably, BDG is not highly expressed in Cryptococcus fungi. The
test was initially developed for blood sampling, with levels <60 pg/
ml negative, 60–80 pg/ml indeterminate, and >80 pg/ml positive.3
According to Viracor, a BDG assay manufacturer, there is no
determined reference range for CSF. Despite this fact, physicians
have evaluated the utility of BDG testing of CSF with impressive
results.
One study demonstrated that a cut-off level of 138 pg/ml
revealed Candida meningitis with a sensitivity of 98% and
speciﬁcity of 100%, whereas another showed that a cut-off level
as low as 66 pg/ml had 91% sensitivity and 92% speciﬁcity in the
setting of probable meningitis.3,4 Others have reported that a CSF
BDG cut-off value of 110 pg/ml can diagnose CNS fungal infections
with a sensitivity of 100% and speciﬁcity of 96%.5 Furthermore,
another study found BDG levels to be useful for evaluating the
response to therapy, as physicians monitored serial CSF BDG
measurements in patients with fungal meningitis receiving
treatment until they eventually fell below 31 pg/ml.6
In the current case, only one out of four fungal CSF cultures grew
C. albicans, and only sparsely. This is consistent with previous
observations and demonstrates the poor sensitivity of this
diagnostic approach.3,4 Furthermore, serum BDG testing was
consistently negative, in agreement with prior reports on serum
BDG levels in CNS fungal infections.7 On the other hand, BDG
testing of the CSF revealed levels >500 pg/ml, which is well above
reported cut-off values for this assay.
This case report demonstrates a rare complication of IVDA and
supports CSF BDG testing as a viable option for the diagnosis of
Candida meningitis.
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